HB 303-FN (2024): relative to insurance coverage for pain management services.
Cite this page
Granite Record indexes the General Court’s record; it is not that record. Where a citation allows only one source, cite the General Court — every page here links to what it is drawn from. The date below is the day the page was read.
- MLA
- “HB 303-FN (2024): relative to insurance coverage for pain management services.” Granite Record, https://graniterecord.org/bill/2024/hb303. Accessed 24 Oct. 2026.
- APA
- Granite Record. (n.d.). HB 303-FN (2024): relative to insurance coverage for pain management services. Retrieved 24 Oct. 2026, from https://graniterecord.org/bill/2024/hb303
- Chicago
- Granite Record. “HB 303-FN (2024): relative to insurance coverage for pain management services.” Accessed 24 Oct. 2026. https://graniterecord.org/bill/2024/hb303.
- BibTeX
@misc{bill-2024-hb303, title = {HB 303-FN (2024): relative to insurance coverage for pain management services.}, howpublished = {Granite Record}, url = {https://graniterecord.org/bill/2024/hb303}, note = {Accessed 24 Oct. 2026} }
HB 303-FN (2024)
relative to insurance coverage for pain management services.
- Status: Referred for interim study
- Term: 2023-2024
- House committee: Commerce and Consumer Affairs
- Subject: Insurance
The Story
It was introduced on January 5, 2023 and referred to the House Commerce and Consumer Affairs committee. The committee held a public hearing on January 18, 2023. The committee held work sessions on February 8, 2023 and March 8, 2023. The committee met in executive session on March 8, 2023 to vote on its recommendation. The committee retained the bill, holding it for further work rather than reporting it out this year. The committee held work sessions on September 20, 2023 and October 17, 2023. The committee met in executive session on November 8, 2023 to vote on its recommendation. The committee held a work session on November 8, 2023. The committee voted unanimously, 19–0, to recommend that the House study it after the session ends, and the report was placed on the consent calendar. On January 3, 2024 the House voted to study it after the session ends on a voice vote. The committee held a work session on September 12, 2024. The committee met in executive session on October 17, 2024 to vote on its recommendation. The committee reported back on its interim study of the bill: “Not Recommended for Future Legislation”, by a vote of 16 to 0.
Sponsors
- Rep. David Nagel (D - Belk 6) (prime sponsor)
- Rep. Gary Merchant (D - Sull 6)
Hearings and Sessions
- January 18, 2023, 2:15 PM: public hearing, House Commerce and Consumer Affairs, LOB 302-304
- February 8, 2023, 10:45 AM: subcommittee work session, House Commerce and Consumer Affairs, LOB 302-304
- March 8, 2023, 10:00 AM: subcommittee work session, House Commerce and Consumer Affairs, LOB 302-304
- March 8, 2023, 1:15 PM: executive session, House Commerce and Consumer Affairs, LOB 302-304
- September 20, 2023, 1:15 PM: subcommittee work session, House Commerce and Consumer Affairs, LOB 302-304
- October 17, 2023, 1:45 PM: subcommittee work session, House Commerce and Consumer Affairs, LOB 302-304
- November 8, 2023, 10:45 AM: subcommittee work session, House Commerce and Consumer Affairs, LOB 302-304
- November 8, 2023, 1:30 PM: executive session, House Commerce and Consumer Affairs, LOB 302-304
- September 12, 2024, 10:00 AM: full committee work session, House Commerce and Consumer Affairs, LOB 302-304
- October 17, 2024, 10:00 AM: executive session, House Commerce and Consumer Affairs, LOB 302-304
Votes
- January 3, 2024, House: Refer for Interim Study — voice vote, passed
The Docket
- January 5, 2023: Introduced (in recess of) 01/05/2023 and referred to Commerce and Consumer Affairs
- January 18, 2023: Public Hearing: 01/18/2023 02:15 pm LOB 302-304
- February 8, 2023: Subcommittee Work Session: 02/08/2023 10:45 am LOB 302-304
- March 8, 2023: Subcommittee Work Session: 03/08/2023 10:00 am LOB 302-304
- March 8, 2023: Executive Session: 03/08/2023 01:15 pm LOB 302-304
- March 13, 2023: Retained in Committee
- September 6, 2023: ==CANCELLED== Subcommittee Work Session: 09/06/2023 01:15 pm LOB 302-304
- September 20, 2023: Subcommittee Work Session: 09/20/2023 01:15 pm LOB 302-304
- October 17, 2023: Subcommittee Work Session: 10/17/2023 01:45 pm LOB 302-304
- November 8, 2023: Executive Session: 11/08/2023 01:30 pm LOB 302-304
- November 8, 2023: Subcommittee Work Session: 11/08/2023 10:45 am LOB 302-304
- November 8, 2023: Committee Report: Refer for Interim Study 11/08/2023 (Vote 19-0; CC)
- November 15, 2023: ==CANCELLED== Executive Session: 11/15/2023 11:00 am LOB 302-304
- January 3, 2024: Refer for Interim Study: MA VV 01/03/2024
- September 12, 2024: Full Committee Work Session: 09/12/2024 10:00 am LOB 302-304
- October 17, 2024: Executive Session: 10/17/2024 10:00 am LOB 302-304
- October 31, 2024: Interim Study Report: Not Recommended for Future Legislation (Vote 16-0)
Laws It Would Change
Related Bills
- HB 554-FN (2024): relative to treatment alternatives to opioids.